A Multicenter, Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors.

Trial Profile

A Multicenter, Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2013

At a glance

  • Drugs JI 101 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Apr 2012 Actual end date Jan 2012 added as reported by ClinicalTrials.gov.
    • 20 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Aug 2010 Planned end date changed from 1 Mar 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top